drugset / Trial / NCT06394622
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC729 in the treatment of advanced malignant solid tumors. Condition or disease:advanced malignant solid tumors. Intervention/treatment:Biological: CD70 CAR-NKT cells. Phase:I
Timeline
- Start
- 2024-04-11
- Primary completion
- 2026-06-28
- Completion
- 2026-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CGC729 | Cell therapy | 5e+06 unknown | Other |
| Subject | CGC729 | Cell therapy | 1.5e+07 unknown | Other |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |